Voyager Therapeutics (VYGR) Misses Q2 EPS by 4c

Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.57), $0.04 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $9.5 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Curaleaf pushes back on Aurora's rejection of takeover bid
• Increasing unusual call volume: GPRO ALLY PCG RSI EYPT NRG VYX DPRO GTLB CWH